Mylan Pharmaceuticals has announced that it has approval from the U.S. Food and Drug Administration (FDA) for its generic version of the drug Cytomel. Mylan has already begun to ship Liothyronine Sodium Tablets USP in three sizes that match Cytomel's dosages: 5 mcg, 25 mcg, and 50 mcg.
Mylan's liothyronine sodium tablets are the generic version of King Pharmaceuticals' drug Cytomel®, which is a synthetic form of the T3 hormone. Cytomel had total U.S. sales of approximately $54 million for the 12 months ending March 31, 2009.
Synthetic T3 is used as an adjunct to levothyroxine or desiccated thyroid treatment in some patients with hypothyroidism, as thyroid hormone replacement for some thyroid cancer patients prior to scans, and in rare cases, as a sole form of thyroid hormone replacement.
Source: Mylan Pharmaceuticals
About Mary Shomon | Thyroid Forum | Twitter | Facebook